• LAST PRICE
    8.1950
  • TODAY'S CHANGE (%)
    Trending Down-0.1050 (-1.2651%)
  • Bid / Lots
    6.0000/ 1
  • Ask / Lots
    10.0500/ 1
  • Open / Previous Close
    8.4150 / 8.3000
  • Day Range
    Low 8.0000
    High 8.5500
  • 52 Week Range
    Low 8.0000
    High 41.5500
  • Volume
    17,559
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 8.3
TimeVolumeTPST
10:06 ET1008.415
10:11 ET1008.2
10:13 ET1008.06
10:20 ET3008.06
10:45 ET2918.06
10:47 ET11908
10:51 ET1008.0754
11:39 ET1008.085
12:44 ET8748.045
12:48 ET2008.02
12:50 ET1008.02
01:02 ET1008.02
01:11 ET1008.04
01:26 ET2008.02
01:33 ET1008.02
01:36 ET1008.02
01:47 ET1008.02
01:56 ET1008.02
02:21 ET3008.02
02:32 ET1008
02:48 ET21008.0321
02:50 ET22898.2284
02:52 ET11008.32
02:54 ET10008.4783
02:56 ET4008.275
02:57 ET10008.55
03:03 ET10008.4958
03:15 ET1008.33
03:33 ET6008.1101
03:39 ET1008.29
03:57 ET1008.195
04:00 ET6008.195
Data delayed at least 15 minutes.

Nov 18, 2021

Nov 12, 2021

Nov 8, 2021

0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesTPST
Tempest Therapeutics Inc
56.6M
-0.4x
---
United StatesGLMD
Galmed Pharmaceuticals Ltd
56.4M
-1.5x
---
United StatesELDN
Eledon Pharmaceuticals Inc
57.5M
-1.0x
---
United StatesADIL
Adial Pharmaceuticals Inc
55.4M
-2.6x
---
United StatesMACK
Merrimack Pharmaceuticals Inc
55.4M
-17.9x
---
United StatesOGEN
Oragenics Inc
57.9M
-2.7x
---
As of 2021-12-04

Company Information

Tempest Therapeutics, Inc.(Tempest), formerly Millendo Therapeutics, Inc., is a clinical-stage oncology company. The Company is focused on developing therapeutics that combine both targeted and immune-mediated mechanisms to treat a wide range of tumors. The Company’s two clinical programs are TPST-1495 and TPST-1120. The Company's both TPST-1495 and TPST-1120 are advancing through Phase 1 studies designed to study both agents as monotherapies and in combination with other approved agents. Tempest is also developing an orally-available inhibitor of TREX-1 designed to activate cGAS/STING pathway, an innate immune response pathway important for the development of anti-tumor immunity.

Contact Information

Headquarters
7000 SHORELINE COURT, SUITE 275SOUTH SAN FRANCISCO, CA, United States 94080
Phone
415-798-8589
Fax
302-655-5049

Executives

Chairman of the Board
Mike Raab
President, Director
Tom Dubensky
Chief Executive Officer, Director
Stephen Brady
Chief Financial Officer, Vice President - Strategy and Finance
Nicholas Maestas
Chief Commercial Officer
Thomas Hoover

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$56.6M
Revenue (TTM)
$0.00
Shares Outstanding
6.9M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.44
EPS
$-21.16
Book Value
$26.10
P/E Ratio
-0.4x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.